Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003003 · ClinicalTrials.gov registry record · Phase 1
Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia
A Phase 1 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00003003: Completed Phase 1 study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT00003003 is a Phase 1 study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 29 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003003, a Phase 1 study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers become resistant to chemotherapy drugs. Combining mitomycin with a chemotherapy drug may reduce resistance to the drug and allow the cancer cells to be killed. PURPOSE: Phase I trial to study the effectiveness of mitomycin and mitoxantrone in treating patients with acute myelogenous leukemia and to determine whether mitomycin can reduce the cancer's resistance to chemotherapy.
Interventions
- BIOLOGICAL sargramostim
- DRUG mitoxantrone hydrochloride
- DRUG mitomycin C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 1996-09 |
| Est. Completion | 2000-08 |
| Phase | Phase 1 |
What the finished NCT00003003 record still lists
NCT00003003 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 3 interventions - of which sargramostim is the first listed.
NCT00003003 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003003 about?
NCT00003003 is a clinical study titled "Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers become resistant to chemotherapy drugs. Combining mitomycin with a chemotherapy drug may reduce resistance to the drug and allow the cancer cells to be killed. PURPO...
What is the current status of trial NCT00003003?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 1996-09. Estimated completion is 2000-08.
What interventions are being tested in trial NCT00003003?
The interventions under investigation include: sargramostim (BIOLOGICAL), mitoxantrone hydrochloride (DRUG), mitomycin C (DRUG).
Who is sponsoring clinical trial NCT00003003?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003003's enrollment target sits among peer trials
29 1440th of 2000 higher than 554 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia